These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24594478)

  • 1. Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug.
    Hutson PH; Pennick M; Secker R
    Neuropharmacology; 2014 Dec; 87():41-50. PubMed ID: 24594478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
    Boellner SW; Stark JG; Krishnan S; Zhang Y
    Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder.
    Adler LA; Alperin S; Leon T; Faraone SV
    J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):196-199. PubMed ID: 27935735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity profile of lisdexamfetamine dimesylate in three independent rat toxicology studies.
    Krishnan S; Montcrief S
    Basic Clin Pharmacol Toxicol; 2007 Oct; 101(4):231-40. PubMed ID: 17845504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.
    Ermer J; Homolka R; Martin P; Buckwalter M; Purkayastha J; Roesch B
    J Clin Pharmacol; 2010 Sep; 50(9):1001-10. PubMed ID: 20173084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers.
    Jasinski DR; Krishnan S
    J Psychopharmacol; 2009 Jun; 23(4):410-8. PubMed ID: 18635707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers.
    Krishnan SM; Stark JG
    Curr Med Res Opin; 2008 Jan; 24(1):33-40. PubMed ID: 18021493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lisdexamfetamine and immediate release d-amfetamine - differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity.
    Rowley HL; Kulkarni R; Gosden J; Brammer R; Hackett D; Heal DJ
    Neuropharmacology; 2012 Nov; 63(6):1064-74. PubMed ID: 22796358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse.
    Jasinski DR; Krishnan S
    J Psychopharmacol; 2009 Jun; 23(4):419-27. PubMed ID: 19329547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults.
    Ermer JC; Haffey MB; Doll WJ; Martin P; Sandefer EP; Dennis K; Corcoran M; Trespidi L; Page RC
    Drug Metab Dispos; 2012 Feb; 40(2):290-7. PubMed ID: 22039171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of lisdexamfetamine dimesylate for the treatment of ADHD.
    Childress AC; Sallee FR
    Expert Rev Neurother; 2012 Jan; 12(1):13-26. PubMed ID: 22243042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.
    Roesch B; Corcoran ME; Fetterolf J; Haffey M; Martin P; Preston P; Purkayastha J; Wang P; Ermer J
    Drugs R D; 2013 Jun; 13(2):119-28. PubMed ID: 23615868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy.
    Ermer JC; Pennick M; Frick G
    Clin Drug Investig; 2016 May; 36(5):341-56. PubMed ID: 27021968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative Bioavailabilities of Lisdexamfetamine Dimesylate and D-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or Drink.
    Ermer J; Corcoran M; Lasseter K; Martin PT
    Ther Drug Monit; 2016 Dec; 38(6):769-776. PubMed ID: 27661399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder.
    Ward K; Citrome L
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):229-238. PubMed ID: 29258368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lisdexamfetamine.
    Blick SK; Keating GM
    Paediatr Drugs; 2007; 9(2):129-35; discussion 136-8. PubMed ID: 17407369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lisdexamfetamine dimesylate: a prodrug stimulant for the treatment of ADHD in children and adults.
    Mattingly G
    CNS Spectr; 2010 May; 15(5):315-25. PubMed ID: 20448522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in the neurochemical and behavioural profiles of lisdexamfetamine methylphenidate and modafinil revealed by simultaneous dual-probe microdialysis and locomotor activity measurements in freely-moving rats.
    Rowley HL; Kulkarni RS; Gosden J; Brammer RJ; Hackett D; Heal DJ
    J Psychopharmacol; 2014 Mar; 28(3):254-69. PubMed ID: 24327450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lisdexamfetamine: A pharmacokinetic review.
    Comiran E; Kessler FH; Fröehlich PE; Limberger RP
    Eur J Pharm Sci; 2016 Jun; 89():172-9. PubMed ID: 27125257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.